OXSORALEN-ULTRA
LOE ApproachingNDAORALCAPSULE
Approved
Oct 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXSORALEN-ULTRA is an oral capsule formulation approved in 1986 for photochemotherapy indications. The drug's mechanism of action involves psoralen compounds that, when combined with UVA light exposure, treat dermatological conditions. Specific mechanism and indication details are not available in current data.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), this product is in defensive commercial mode with limited team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OXSORALEN-ULTRA currently shows zero linked job openings, reflecting its mature LOE-approaching lifecycle status. Career opportunities on this product are limited and focused on maintaining market share rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on OXSORALEN-ULTRA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.